Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

about

Migraine Therapy: Current Approaches and New Horizons.Polypharmacy Among Headache Patients: A Cross-Sectional Study

P2860

Q52581504-AF80F263-8615-48C9-B5E9-2935988E41CE Q58896340-0C87C1EF-8F26-48FA-B47F-DA1BC781E464

P2860

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

Item

http://www.wikidata.org/entity/Q55084349

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

@en

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

@nl

type

Item

label

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

@en

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

@nl

prefLabel

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

@en

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

@nl

P1476

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

@en

P2093

Philip R Holland

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

The International Classification of Headache Disorders, 3rd edition (beta version)

Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine.

Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-relate

Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat.

Liver enzyme alteration: a guide for clinicians.

A neurohistochemical blueprint for pain-induced loss of appetite.

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study.

Possible site of action of CGRP antagonists in migraine.

Diencephalic and brainstem mechanisms in migraine.

P2888

s13311-018-0617-4

P304

304-312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S13311-018-0617-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter J. Goadsby

P5008

ScienceSource

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101629333

http://www.w3.org/2001/XMLSchema#string

P698

29556965

http://www.w3.org/2001/XMLSchema#string

P921

migraine disorder

mechanism of action

P932

5935646

http://www.w3.org/2001/XMLSchema#string

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

about

P2860

P2860

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P5008

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P5008

P577

P6179

P698

P921

P932